Youping Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Youping Wang has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Lin Cui
Division of Cardiology, First Affiliated Hospital, Henan University of Traditional Chinese Medicine
7 shared publications- Mingjun Zhu
Department of Cardiovascular Disease, The first Affiliated Hospital of Henan University of Chinese Medicine
5 shared publications Shiyu Zhang
Division of Cardiology, First Affiliated Hospital, Henan University of Traditional Chinese Medicine
4 shared publications- Lin Cui
Division of Cardiology and Central Laboratory, First Affiliated Hospital, Henan University of Traditional Chinese Medicine, Zhengzhou, 450000, People’s Republic of China
3 shared publications Shiyang Xie
Central Laboratory and Division of Cardiology, First Affiliated Hospital, Henan University of Traditional Chinese Medicine, Zhengzhou, China
3 shared publicationsSi Shen
Central Laboratory and Division of Cardiology, First Affiliated Hospital, Henan University of Traditional Chinese Medicine, Zhengzhou, 450000, China
3 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1867891
Effects and potential mechanisms of astragaloside IV in animal models of renal fibrosis: a systematic review and meta-analysis
Background: Renal fibrosis is the principal pathological hallmark of progressive chronic kidney disease (CKD). However, the clinical availability of effective, targeted anti-fibrotic therapeutics remains severely constrained. Astragaloside IV (AS-IV), a predominant bioactive metabolite isolated from Astragali Radix, has exhibited substantial renoprotective and anti-fibrotic properties in diverse preclinical models. Materials and Methods: We systematically searched eight electronic databases (PubMed, Web of Science, Embase, ProQuest, CNKI, SinoMed, VIP, and Wanfang Data) from inception to 30 November 2025, to identify relevant in vivo studies. Risk of bias was assessed using the SYRCLE tool. Statistical analyses were performed using Review Manager 5.3 and Stata 18.0. Results: A total of 34 studies involving 769 animals were included. Compared with the control group, AS-IV treatment significantly reduced the levels of serum creatinine (Scr), blood urea nitrogen (BUN), proteinuria, transforming growth factor-β1 (TGF-β1), fibronectin, and α-smooth muscle actin (α-SMA) (all P < 0.0001). Subgroup analyses revealed that intragastric dose was a source of heterogeneity for Scr; publication year for BUN; treatment duration for TGF-β1; and the underlying animal disease model alongside treatment duration for α-SMA. Dose-response analyses revealed that Scr, BUN, TGF-β1, fibronectin, and α-SMA showed overall negative dose-dependent trends. In addition, AS-IV significantly modulated the expression of other indicators related to fibrosis, oxidative stress, and inflammatory responses. Methodologically, the overall quality of the included studies was suboptimal, and there was considerable statistical heterogeneity. Additionally, the presence of publication bias cannot be definitively excluded. These results suggest that AS-IV holds renoprotective potential in animal models of renal fibrosis; however, these results should be interpreted prudently. Conclusion: This study provides the first systematic review evaluating AS-IV across etiologically diverse models of renal fibrosis, showing its broad-spectrum anti-fibrotic pharmacological effects. The synthesized evidence suggests that these renoprotective effects may be mediated through multi-target modulation, including mitigating inflammation and oxidative stress, modulating autophagy and apoptosis, and reducing extracellular matrix (ECM) accumulation. Nevertheless, given the significant heterogeneity and overall suboptimal methodological quality of the included studies, these positive findings should be interpreted with caution. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261372263 , identifier CRD420261372263.
- 25 August 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1867891
Open AccessEffects and potential mechanisms of astragaloside IV in animal models of renal fibrosis: a systematic review and meta-analysis
Background: Renal fibrosis is the principal pathological hallmark of progressive chronic kidney disease (CKD). However, the clinical availability of effective, targeted anti-fibrotic therapeutics remains severely constrained. Astragaloside IV (AS-IV), a predominant bioactive metabolite isolated from Astragali Radix, has exhibited substantial renoprotective and anti-fibrotic properties in diverse preclinical models. Materials and Methods: We systematically searched eight electronic databases (PubMed, Web of Science, Embase, ProQuest, CNKI, SinoMed, VIP, and Wanfang Data) from inception to 30 November 2025, to identify relevant in vivo studies. Risk of bias was assessed using the SYRCLE tool. Statistical analyses were performed using Review Manager 5.3 and Stata 18.0. Results: A total of 34 studies involving 769 animals were included. Compared with the control group, AS-IV treatment significantly reduced the levels of serum creatinine (Scr), blood urea nitrogen (BUN), proteinuria, transforming growth factor-β1 (TGF-β1), fibronectin, and α-smooth muscle actin (α-SMA) (all P < 0.0001). Subgroup analyses revealed that intragastric dose was a source of heterogeneity for Scr; publication year for BUN; treatment duration for TGF-β1; and the underlying animal disease model alongside treatment duration for α-SMA. Dose-response analyses revealed that Scr, BUN, TGF-β1, fibronectin, and α-SMA showed overall negative dose-dependent trends. In addition, AS-IV significantly modulated the expression of other indicators related to fibrosis, oxidative stress, and inflammatory responses. Methodologically, the overall quality of the included studies was suboptimal, and there was considerable statistical heterogeneity. Additionally, the presence of publication bias cannot be definitively excluded. These results suggest that AS-IV holds renoprotective potential in animal models of renal fibrosis; however, these results should be interpreted prudently. Conclusion: This study provides the first systematic review evaluating AS-IV across etiologically diverse models of renal fibrosis, showing its broad-spectrum anti-fibrotic pharmacological effects. The synthesized evidence suggests that these renoprotective effects may be mediated through multi-target modulation, including mitigating inflammation and oxidative stress, modulating autophagy and apoptosis, and reducing extracellular matrix (ECM) accumulation. Nevertheless, given the significant heterogeneity and overall suboptimal methodological quality of the included studies, these positive findings should be interpreted with caution. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261372263 , identifier CRD420261372263.
- Open Access
- 22 April 2025
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 63 (1) , 250-263
Anti-fibrosis effect of astragaloside IV in animal models of cardiovascular diseases and its mechanisms: a systematic review
Myocardial fibrosis is a common manifestation of end-stage cardiovascular disease, but there is a lack of means to reverse fibrosis. Astragaloside IV (AS-IV), the major active component of Astragalus membranaceus Fisch. ex Bunge Fabaceae, possesses diverse biological activities that have beneficial effects against cardiovascular disease. This systematic review aims to summarize the anti-fibrosis effect of AS-IV in animal models (rats or mice only) and its underlying mechanisms, and provide potential directions for the clinical use of AS-IV. PubMed, EMBASE, Web of Science, CNKI, Wanfang database, and SinoMed were searched from inception to 31 December 2024. The following characteristics of the included studies were extracted and summarized: animal model, route of administration, dose/concentration, measurement indicators, and potential mechanisms. The quality of the included studies was assessed used a 10-item scale from SYRCLE. AS-IV represents a promising multi-target candidate for myocardial fibrosis treatment in the 24 eligible studies included in the analysis. This systematic review is the first to comprehensively evaluate the anti-fibrosis mechanisms of AS-IV across heterogeneous cardiovascular disease animal models, including myocardial infarction, hypertension, ischemia-reperfusion injury, and myocarditis. The underlying mechanisms of the anti-fibrosis effects of AS-IV may include collagen metabolism, anti-apoptosis, anti-inflammation and, pyroptosis, antioxidants, improving mitochondrial function, regulating senescence, etc. Current evidence remains preclinical, with critical gaps in toxicological profiles, human safety thresholds, and clinical adverse reaction data. Future research must integrate robust toxicological evaluations, optimized combination therapies, and adaptive clinical trials to validate translational potential.
- 22 April 2025
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 63 (1) , 250-263
Open AccessAnti-fibrosis effect of astragaloside IV in animal models of cardiovascular diseases and its mechanisms: a systematic review
Myocardial fibrosis is a common manifestation of end-stage cardiovascular disease, but there is a lack of means to reverse fibrosis. Astragaloside IV (AS-IV), the major active component of Astragalus membranaceus Fisch. ex Bunge Fabaceae, possesses diverse biological activities that have beneficial effects against cardiovascular disease. This systematic review aims to summarize the anti-fibrosis effect of AS-IV in animal models (rats or mice only) and its underlying mechanisms, and provide potential directions for the clinical use of AS-IV. PubMed, EMBASE, Web of Science, CNKI, Wanfang database, and SinoMed were searched from inception to 31 December 2024. The following characteristics of the included studies were extracted and summarized: animal model, route of administration, dose/concentration, measurement indicators, and potential mechanisms. The quality of the included studies was assessed used a 10-item scale from SYRCLE. AS-IV represents a promising multi-target candidate for myocardial fibrosis treatment in the 24 eligible studies included in the analysis. This systematic review is the first to comprehensively evaluate the anti-fibrosis mechanisms of AS-IV across heterogeneous cardiovascular disease animal models, including myocardial infarction, hypertension, ischemia-reperfusion injury, and myocarditis. The underlying mechanisms of the anti-fibrosis effects of AS-IV may include collagen metabolism, anti-apoptosis, anti-inflammation and, pyroptosis, antioxidants, improving mitochondrial function, regulating senescence, etc. Current evidence remains preclinical, with critical gaps in toxicological profiles, human safety thresholds, and clinical adverse reaction data. Future research must integrate robust toxicological evaluations, optimized combination therapies, and adaptive clinical trials to validate translational potential.
- Open Access
- 1 March 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 3951-3967
Astragaloside IV Attenuates Angiotensin II-Induced Inflammatory Responses in Endothelial Cells: Involvement of Mitochondria
Background: Angiotensin II (Ang II)-triggered endothelial inflammation is a critical mechanism contributing to Ang II-related cardiovascular diseases. The inflammation is highly correlated with mitochondrial function. Although astragaloside IV (AS-IV), a primary bioactive ingredient extracted from the traditional Chinese medicine Astragalus membranaceus Bunge that can effectively treat numerous cardiovascular diseases, posses the actions of antiinflammation and antioxidation in vivo, limited data are made available on the impacts of AS-IV on mitochondrial function in endothelial inflammation triggered by Ang II. This study was performed to evaluate the in vitro actions of AS-IV on Ang II-triggered inflammatory responses in endothelial cells, and to further clarify the potential role of mitochondria in the actions. Methods: Human umbilical vein endothelial cells (HUVECs) were preincubated with AS-IV and then exposed to Ang II for 12 h. Results: The exposure of HUVECs to Ang II triggered cytokine and chemokine production, the upregulation of adhesive molecules, monocyte attachment, and nuclear factor-kappa B activation. Additionally, our results showed that the inflammatory responses triggered by Ang II were associated with the impairment of mitochondrial function, as evidenced by the reductions of mitochondrial membrane potential, ATP synthesis, and mitochondrial complexes I and III activities. Moreover, the concentrations of malondialdehyde, cellular reactive oxygen species, and mitochondrial superoxide enhanced after HUVECs challenged with Ang II, which were concurrent with the decreases in total superoxide dismutase (SOD) and its isoenzyme activities such as Mn-SOD. These Ang II–induced alterations were reversed by preincubation with AS-IV. Conclusion: Our data indicate that AS-IV attenuates Ang II-triggered endothelial inflammation possibly via ameliorating mitochondrial function.
- 1 March 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 3951-3967
Open AccessAstragaloside IV Attenuates Angiotensin II-Induced Inflammatory Responses in Endothelial Cells: Involvement of Mitochondria
Background: Angiotensin II (Ang II)-triggered endothelial inflammation is a critical mechanism contributing to Ang II-related cardiovascular diseases. The inflammation is highly correlated with mitochondrial function. Although astragaloside IV (AS-IV), a primary bioactive ingredient extracted from the traditional Chinese medicine Astragalus membranaceus Bunge that can effectively treat numerous cardiovascular diseases, posses the actions of antiinflammation and antioxidation in vivo, limited data are made available on the impacts of AS-IV on mitochondrial function in endothelial inflammation triggered by Ang II. This study was performed to evaluate the in vitro actions of AS-IV on Ang II-triggered inflammatory responses in endothelial cells, and to further clarify the potential role of mitochondria in the actions. Methods: Human umbilical vein endothelial cells (HUVECs) were preincubated with AS-IV and then exposed to Ang II for 12 h. Results: The exposure of HUVECs to Ang II triggered cytokine and chemokine production, the upregulation of adhesive molecules, monocyte attachment, and nuclear factor-kappa B activation. Additionally, our results showed that the inflammatory responses triggered by Ang II were associated with the impairment of mitochondrial function, as evidenced by the reductions of mitochondrial membrane potential, ATP synthesis, and mitochondrial complexes I and III activities. Moreover, the concentrations of malondialdehyde, cellular reactive oxygen species, and mitochondrial superoxide enhanced after HUVECs challenged with Ang II, which were concurrent with the decreases in total superoxide dismutase (SOD) and its isoenzyme activities such as Mn-SOD. These Ang II–induced alterations were reversed by preincubation with AS-IV. Conclusion: Our data indicate that AS-IV attenuates Ang II-triggered endothelial inflammation possibly via ameliorating mitochondrial function.
- Open Access
- 1 January 2024
- Published by Wiley in Mediators of Inflammation
- Vol. 2024 (1)
The Role of Ca2+/PI3K/Akt/eNOS/NO Pathway in Astragaloside IV–Induced Inhibition of Endothelial Inflammation Triggered by Angiotensin II
Inflammation induced by angiotensin II (Ang II) is a key event in the progression of numerous cardiovascular diseases. Astragaloside IV (AS‐IV), a glycoside extracted from Astragalus membranaceus Bunge, has been shown to inhibit Ang II–induced inflammatory responses in vivo. However, the mechanisms underlying the beneficial effects are still unclear. This study investigated whether AS‐IV attenuates endothelial inflammation induced by Ang II via the activation of endothelial nitric oxide synthase (eNOS)/nitric oxide (NO) pathway. Human umbilical vein endothelial cells (HUVECs) were cultured in the presence of AS‐IV with or without the specific inhibitor of NOS or Ca2+‐ and phosphatidylinositol 3‐kinase (PI3K)/Akt‐dependent cascade prior to Ang II exposure. Incubation of HUVECs with AS‐IV enhanced NO production and eNOSser1177 phosphorylation. These responses were abrogated by the inhibition of NOS or Ca2+‐ and PI3K/Akt‐dependent pathway. In addition, preincubation of HUVECs with AS‐IV inhibited Ang II–induced cytokine and chemokine production, adhesion molecule expression, monocyte adhesion, and nuclear factor kappa B (NF‐κB) activation as evidenced by the attenuation of inhibitor of kappa B alpha phosphorylation and subsequent NF‐κB DNA binding. These effects of AS‐IV were abolished by the suppression of NOS or Ca2+‐ and PI3K/Akt‐dependent cascade. Our findings indicate that AS‐IV attenuates inflammatory responses triggered by Ang II possibly via the activation of Ca2+/PI3K/Akt/eNOS/NO pathway in endothelial cells.
- 1 January 2024
- Published by Wiley in Mediators of Inflammation
- Vol. 2024 (1)
Open AccessThe Role of Ca2+/PI3K/Akt/eNOS/NO Pathway in Astragaloside IV–Induced Inhibition of Endothelial Inflammation Triggered by Angiotensin II
Inflammation induced by angiotensin II (Ang II) is a key event in the progression of numerous cardiovascular diseases. Astragaloside IV (AS‐IV), a glycoside extracted from Astragalus membranaceus Bunge, has been shown to inhibit Ang II–induced inflammatory responses in vivo. However, the mechanisms underlying the beneficial effects are still unclear. This study investigated whether AS‐IV attenuates endothelial inflammation induced by Ang II via the activation of endothelial nitric oxide synthase (eNOS)/nitric oxide (NO) pathway. Human umbilical vein endothelial cells (HUVECs) were cultured in the presence of AS‐IV with or without the specific inhibitor of NOS or Ca2+‐ and phosphatidylinositol 3‐kinase (PI3K)/Akt‐dependent cascade prior to Ang II exposure. Incubation of HUVECs with AS‐IV enhanced NO production and eNOSser1177 phosphorylation. These responses were abrogated by the inhibition of NOS or Ca2+‐ and PI3K/Akt‐dependent pathway. In addition, preincubation of HUVECs with AS‐IV inhibited Ang II–induced cytokine and chemokine production, adhesion molecule expression, monocyte adhesion, and nuclear factor kappa B (NF‐κB) activation as evidenced by the attenuation of inhibitor of kappa B alpha phosphorylation and subsequent NF‐κB DNA binding. These effects of AS‐IV were abolished by the suppression of NOS or Ca2+‐ and PI3K/Akt‐dependent cascade. Our findings indicate that AS‐IV attenuates inflammatory responses triggered by Ang II possibly via the activation of Ca2+/PI3K/Akt/eNOS/NO pathway in endothelial cells.
- Open Access
- 21 July 2022
- Published by Elsevier in Current Therapeutic Research
- Vol. 97, 100683
Triptolide Alleviates Oxidized LDL-Induced Endothelial Inflammation by Attenuating the Oxidative Stress-Mediated Nuclear Factor-Kappa B Pathway
- 21 July 2022
- Published by Elsevier in Current Therapeutic Research
- Vol. 97, 100683
Open AccessTriptolide Alleviates Oxidized LDL-Induced Endothelial Inflammation by Attenuating the Oxidative Stress-Mediated Nuclear Factor-Kappa B Pathway
- Open Access
- 29 January 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-10
Protective Effects of Shenfuyixin Granule on H2O2-Induced Apoptosis in Neonatal Rat Cardiomyocytes
Shenfuyixin granule (SFYXG, i.e., Xinshuaikang granule) is a prescription, commonly used in the clinical experience, which plays a significant role in the treatment of heart failure. The purpose of this present research was to investigate the protective effect of SFYXG, and the mechanism about anti-H2O2-induced oxidative stress and apoptosis in the neonatal rat cardiomyocytes. Myocardial cells, as is well known, were divided into 4 groups: normal, model, SFYXG, and coenzyme Q10 group, respectively. Cells viability was determined by MTT assay. Flow cytometry and AO/EB staining were implemented to test the apoptosis rate and intracellular reactive oxygen species (ROS) level. Mitochondrion membrane potential (MMP) was evaluated by JC-1 fluorescence probe method. The myocardial ultrastructure of mitochondrion was measured by electron microscope. The related mRNA expression levels of Bax, Bcl-2, Caspase-3, caspase-8, and caspase-9 were detected by real-time polymerase chain reaction (PCR). Also, the expression levels of Bax and Bcl-2 protein were detected by Western blot, and the expression levels of caspase-3, caspase-8, and caspase-9 protein were tested by caspase-Glo®3 Assay, caspase-Glo®8 Assay, and caspase-Glo®9 Assay, respectively. GAPDH was used as the internal reference gene/protein. The results revealed that SFYXG (0.5 mg/ml) raised the viability of myocardial cell, weakened the apoptosis rate and ROS level, corrected the mitochondrion membrane potential stability, and improved cell morphology and ultrastructure of myocardial mitochondrion. Furthermore, SFYXG upregulated the antiapoptosis gene of Bcl-2, but downregulated the proapoptosis genes of Bax, caspase-3, and caspase-9. In conclusion, SFYXG could appear to attenuate myocardial injury by its antioxidative and antiapoptosis effect.
- 29 January 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-10
Open AccessProtective Effects of Shenfuyixin Granule on H2O2-Induced Apoptosis in Neonatal Rat Cardiomyocytes
Shenfuyixin granule (SFYXG, i.e., Xinshuaikang granule) is a prescription, commonly used in the clinical experience, which plays a significant role in the treatment of heart failure. The purpose of this present research was to investigate the protective effect of SFYXG, and the mechanism about anti-H2O2-induced oxidative stress and apoptosis in the neonatal rat cardiomyocytes. Myocardial cells, as is well known, were divided into 4 groups: normal, model, SFYXG, and coenzyme Q10 group, respectively. Cells viability was determined by MTT assay. Flow cytometry and AO/EB staining were implemented to test the apoptosis rate and intracellular reactive oxygen species (ROS) level. Mitochondrion membrane potential (MMP) was evaluated by JC-1 fluorescence probe method. The myocardial ultrastructure of mitochondrion was measured by electron microscope. The related mRNA expression levels of Bax, Bcl-2, Caspase-3, caspase-8, and caspase-9 were detected by real-time polymerase chain reaction (PCR). Also, the expression levels of Bax and Bcl-2 protein were detected by Western blot, and the expression levels of caspase-3, caspase-8, and caspase-9 protein were tested by caspase-Glo®3 Assay, caspase-Glo®8 Assay, and caspase-Glo®9 Assay, respectively. GAPDH was used as the internal reference gene/protein. The results revealed that SFYXG (0.5 mg/ml) raised the viability of myocardial cell, weakened the apoptosis rate and ROS level, corrected the mitochondrion membrane potential stability, and improved cell morphology and ultrastructure of myocardial mitochondrion. Furthermore, SFYXG upregulated the antiapoptosis gene of Bcl-2, but downregulated the proapoptosis genes of Bax, caspase-3, and caspase-9. In conclusion, SFYXG could appear to attenuate myocardial injury by its antioxidative and antiapoptosis effect.
- Open Access
- 1 December 2020
- Published by Elsevier in International Immunopharmacology
- Vol. 89, 107035
Triptolide attenuates renal damage by limiting inflammatory responses in DOCA-salt hypertension
- 1 December 2020
- Published by Elsevier in International Immunopharmacology
- Vol. 89, 107035
Open AccessTriptolide attenuates renal damage by limiting inflammatory responses in DOCA-salt hypertension
- Open Access
- 2 August 2019
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 19 (1) , 1-9
Triptolide attenuates lipopolysaccharide-induced inflammatory responses in human endothelial cells: involvement of NF-κB pathway
Endothelial cell inflammation is a central event in the pathogenesis of numerous cardiovascular diseases, including sepsis and atherosclerosis. Triptolide, a principal bioactive ingredient of Traditional Chinese Medicine Tripterygium wilfordii Hook.F., displays anti-inflammatory actions in vivo. However, the mechanisms underlying these beneficial effects remain undetermined. The present study investigated the effects and possible mechanisms of triptolide on lipopolysaccharide (LPS)-induced inflammatory responses in human umbilical vein endothelial cells (HUVECs). The effects of triptolide on the LPS-induced production and expression of inflammatory molecules, monocyte adhesion and activation of nuclear factor (NF)-κB pathway were examined in cultured HUVECs. In cultured HUVECs, pre-treatment with triptolide dose-dependently attenuated LPS-induced cytokine and chemokine production, adhesion molecule expression and monocyte adhesion. Mechanistically, triptolide was found to dose-dependently inhibit the LPS-induced increases in the DNA binding activity of NF-κB p65 associated with attenuating IκBα phosphorylation and its degradation. Additionally, the present study revealed that triptolide inhibited LPS-triggered NF-κB transcriptional activation in a dose-dependent manner. The results of the present study indicated that triptolide suppresses the inflammatory response of endothelial cells possibly via inhibition of NF-κB activation.
- 2 August 2019
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 19 (1) , 1-9
Open AccessTriptolide attenuates lipopolysaccharide-induced inflammatory responses in human endothelial cells: involvement of NF-κB pathway
Endothelial cell inflammation is a central event in the pathogenesis of numerous cardiovascular diseases, including sepsis and atherosclerosis. Triptolide, a principal bioactive ingredient of Traditional Chinese Medicine Tripterygium wilfordii Hook.F., displays anti-inflammatory actions in vivo. However, the mechanisms underlying these beneficial effects remain undetermined. The present study investigated the effects and possible mechanisms of triptolide on lipopolysaccharide (LPS)-induced inflammatory responses in human umbilical vein endothelial cells (HUVECs). The effects of triptolide on the LPS-induced production and expression of inflammatory molecules, monocyte adhesion and activation of nuclear factor (NF)-κB pathway were examined in cultured HUVECs. In cultured HUVECs, pre-treatment with triptolide dose-dependently attenuated LPS-induced cytokine and chemokine production, adhesion molecule expression and monocyte adhesion. Mechanistically, triptolide was found to dose-dependently inhibit the LPS-induced increases in the DNA binding activity of NF-κB p65 associated with attenuating IκBα phosphorylation and its degradation. Additionally, the present study revealed that triptolide inhibited LPS-triggered NF-κB transcriptional activation in a dose-dependent manner. The results of the present study indicated that triptolide suppresses the inflammatory response of endothelial cells possibly via inhibition of NF-κB activation.
- Open Access
- 21 January 2019
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2019, 1-11
The Guizhi Gancao Decoction Attenuates Myocardial Ischemia-Reperfusion Injury by Suppressing Inflammation and Cardiomyocyte Apoptosis
Guizhi Gancao Decoction (GGD) is a well-known traditional Chinese herbal medicine for the treatment of various cardiovascular diseases, such as myocardial ischemia-reperfusion (I/R) injury and arrhythmia. However, the mechanism by which GGD contributes to the amelioration of cardiac injury remains unclear. The aim of this study was to investigate the potential protective role of GGD against myocardial I/R injury and its possible mechanism. Consistent with the effect of the positive drug (Trimetazidine, TMZ), we subsequently validated that GGD could ameliorate myocardial I/R injury as evidenced by histopathological examination and triphenyltetrazolium chloride (TTC) staining. Moreover, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay demonstrated that GGD suppressed myocardial apoptosis, which may be related to the upregulation of Bcl-2, PPARα, and PPAR and downregulation of Bax, caspase-3, and caspase-9. Pretreatment with GGD attenuated the levels of proinflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin- (IL-) 6, and IL-1β in serum by inhibiting Toll-like receptor 4 (TLR4)/NF-κB signaling pathway. These results indicated that GGD exhibits cardioprotective effects on myocardial I/R injury through inhibition of the TLR4/NF-κB signaling pathway, which led to reduced inflammatory response and the subsequent cardiomyocyte apoptosis.- 21 January 2019
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2019, 1-11
Open AccessThe Guizhi Gancao Decoction Attenuates Myocardial Ischemia-Reperfusion Injury by Suppressing Inflammation and Cardiomyocyte Apoptosis
Guizhi Gancao Decoction (GGD) is a well-known traditional Chinese herbal medicine for the treatment of various cardiovascular diseases, such as myocardial ischemia-reperfusion (I/R) injury and arrhythmia. However, the mechanism by which GGD contributes to the amelioration of cardiac injury remains unclear. The aim of this study was to investigate the potential protective role of GGD against myocardial I/R injury and its possible mechanism. Consistent with the effect of the positive drug (Trimetazidine, TMZ), we subsequently validated that GGD could ameliorate myocardial I/R injury as evidenced by histopathological examination and triphenyltetrazolium chloride (TTC) staining. Moreover, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay demonstrated that GGD suppressed myocardial apoptosis, which may be related to the upregulation of Bcl-2, PPARα, and PPAR and downregulation of Bax, caspase-3, and caspase-9. Pretreatment with GGD attenuated the levels of proinflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin- (IL-) 6, and IL-1β in serum by inhibiting Toll-like receptor 4 (TLR4)/NF-κB signaling pathway. These results indicated that GGD exhibits cardioprotective effects on myocardial I/R injury through inhibition of the TLR4/NF-κB signaling pathway, which led to reduced inflammatory response and the subsequent cardiomyocyte apoptosis. - 1 May 2017
- Published by Elsevier in Atherosclerosis
- Vol. 260, 13-19
TRPV1 agonism inhibits endothelial cell inflammation via activation of eNOS/NO pathway
- 1 May 2017
- Published by Elsevier in Atherosclerosis
- Vol. 260, 13-19
TRPV1 agonism inhibits endothelial cell inflammation via activation of eNOS/NO pathway